Brokerages predict that Allogene Therapeutics Inc (NASDAQ:ALLO) will post ($0.47) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Allogene Therapeutics’ earnings. The lowest EPS estimate is ($0.54) and the highest is ($0.37). The company is scheduled to issue its next quarterly earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Allogene Therapeutics will report full-year earnings of ($1.94) per share for the current fiscal year, with EPS estimates ranging from ($2.10) to ($1.45). For the next fiscal year, analysts forecast that the company will post earnings of ($2.37) per share, with EPS estimates ranging from ($2.89) to ($1.71). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Allogene Therapeutics.

Allogene Therapeutics (NASDAQ:ALLO) last announced its earnings results on Tuesday, May 7th. The company reported ($0.32) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.08.

A number of equities analysts have weighed in on ALLO shares. Cowen reaffirmed a “buy” rating on shares of Allogene Therapeutics in a research note on Friday, March 8th. William Blair reaffirmed a “buy” rating on shares of Allogene Therapeutics in a research note on Monday, April 15th. Stifel Nicolaus started coverage on shares of Allogene Therapeutics in a research note on Wednesday, May 22nd. They issued a “hold” rating and a $27.00 target price for the company. Zacks Investment Research raised shares of Allogene Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 13th. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $29.00 target price on shares of Allogene Therapeutics in a research note on Monday, March 11th. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $35.44.

Shares of NASDAQ ALLO opened at $26.66 on Thursday. Allogene Therapeutics has a 1-year low of $21.67 and a 1-year high of $35.55. The stock has a market capitalization of $3.27 billion and a price-to-earnings ratio of -4.05. The company has a quick ratio of 17.48, a current ratio of 17.48 and a debt-to-equity ratio of 0.05.

In related news, insider Alison Moore sold 48,828 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $26.76, for a total transaction of $1,306,637.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Group Holdings (Sbs) Advis Tpg sold 1,918,755 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $29.38, for a total transaction of $56,373,021.90. The disclosure for this sale can be found here.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC acquired a new position in Allogene Therapeutics during the fourth quarter valued at approximately $27,000. Legal & General Group Plc acquired a new position in Allogene Therapeutics during the fourth quarter valued at approximately $89,000. Partner Investment Management L.P. acquired a new position in Allogene Therapeutics during the fourth quarter valued at approximately $135,000. NumerixS Investment Technologies Inc acquired a new position in Allogene Therapeutics during the first quarter valued at approximately $136,000. Finally, Citigroup Inc. acquired a new position in Allogene Therapeutics during the fourth quarter valued at approximately $152,000. 53.47% of the stock is owned by institutional investors and hedge funds.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.

Read More: Why does a company issue an IPO?

Get a free copy of the Zacks research report on Allogene Therapeutics (ALLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.